GlycoMimetics, Inc.
9780 Medical Center Drive
Rockville
Maryland
20850
United States
292 articles about GlycoMimetics, Inc.
-
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2019
2/28/2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the year and fourth quarter ended December 31, 2019 and highlighted recent company events including several accomplishments reported to date in 2020
-
GlycoMimetics to Present at the Cowen and Company 40th Annual Health Care Conference 2020
2/25/2020
Feb. 25, 2020 14:00 UTC ROCKVILLE, Md.--( BUSINESS WIRE )-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 40th Annual Health Care Conference in Boston, on Tuesday, March 03, 2020, at 12:00 p.m. ET. To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com . About GlycoMimetics
-
GlycoMimetics Advances GMI-1359 Program With Patent Issuance and FDA Designations
2/4/2020
Feb. 4, 2020 14:53 UTC - US Composition of Matter Patent issued - Orphan Drug and Rare Pediatric Disease Designations granted by FDA for treatment of osteosarcoma
-
First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359
1/30/2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Duke University investigators have dosed the first patient in a proof-of-concept Phase 1b study to evaluate GlycoMimetics' novel GMI-1359 drug candidate in patients with advanced breast cancer.
-
GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China
1/6/2020
GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties
-
GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019
11/29/2019
GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31st Annual Healthcare Conference in New York, New York, which takes place on December 3, 2019.
-
GlycoMimetics to Present at Two Upcoming Investor Conferences in November 2019
11/13/2019
GlycoMimetics, Inc. announced that company executives will provide a corporate update at two upcoming investor relations conferences in November.
-
GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments
11/7/2019
Advanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sponsored clinical trials
-
GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting
11/6/2019
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that seven abstracts covering data from the company’s research and clinical portfolio have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando.
-
GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019
10/31/2019
The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.
-
GlycoMimetics to Present at Two Upcoming Investor Conferences
9/5/2019
GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a corporate update at two upcoming investor relations conferences in New York, NY in September.
-
Pfizer's Rivipansel Fails to Meet Primary and Secondary Efficacy Endpoints in Sickle Cell Trial
8/5/2019
The goal of the trial was to evaluate the efficacy and safety of the drug in patients six years of age and older with SCD who were hospitalized for a vaso-occlusive crisis and required treatments with intravenous opioids. -
GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
8/3/2019
GlycoMimetics, Inc. reported that Pfizer Inc. announced that the Phase 3 Rivipansel: Evaluating Safety, Efficacy and Time to Discharge pivotal study did not meet its primary or key secondary efficacy endpoints.
-
GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
8/1/2019
GlycoMimetics, Inc. reported its financial results for the quarter ended June 30, 2019 and highlighted recent business achievements.
-
GlycoMimetics to Report Second Quarter 2019 Financial Results on August 1, 2019
7/25/2019
The dial-in number for the conference call is (844) 413-7154 (U.S. and Canada) or (216) 562-0466 (international) and entering passcode 8268638.
-
GlycoMimetics to Present at Jefferies 2019 Healthcare Conference
5/29/2019
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at the Jefferies 2019 Healthcare Conference, on June 5 at 2:00 p.m. ET. in New York, NY.
-
GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
5/6/2019
Since completion of the Phase 2 clinical trial, Pfizer, has been responsible for clinical development of rivipansel, including the RESET clinical trial.
-
GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights
5/2/2019
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2019 and highlighted recent company achievements
-
GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel
4/29/2019
GlycoMimetics, Inc. announced the addition of two senior executives to its executive management team.
-
GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019
4/25/2019
GlycoMimetics, Inc. announced that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.m. ET.